[Symposium on anti-arrhythmic drugs of the Swedish Society of Cardiology].
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000404:Ajmaline / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001919:Bradycardia / Q000188:drug therapy; D004070:Digitalis / Q000627:therapeutic use; D004562:Electrocardiography; D006321:Heart / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011342:Procainamide / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy
D000318:Adrenergic beta-Agonists; D000889:Anti-Arrhythmia Agents; D000404:Ajmaline; D010672:Phenytoin; D008012:Lidocaine; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide
Cardiologföreningens anti-arytmika-symposium